Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Roche said Phase III IMAgINATION met its primary endpoint, with once-monthly sefaxersen showing statistically significant proteinuria reduction vs placebo at week 37 in adults with IgA nephropathy. Safety was consistent with prior data; the study continues to week 105.Material DetailsContext by AI…
Basel, 23 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive prespecified interim results from the ongoing phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen ac…
Sefaxersen Significantly Reduced Proteinuria Versus Placebo At 37 Weeks, Showing Best-In-Class Potential - Safety Profile Consistent With Earlier Data; No New Safety Signals Identified - Interim Data To Be Presented At Upcoming Medical Meeting And Shared With Health Authorities
Roche: Phase III IMAGINATION Study Met Primary Endpoint
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxe…